Centre for Biological science, K.S.R. College of Arts and Science,
IFN-beta-1b is an effective therapy in multiple sclerosis treatment. Unfortunately, patients develop neutralizing antibodies to the therapy over time with the role of aggregation in instigating immunogenicity debated. BaroFold hypothesized that the removal of aggregates would decrease immunogenicity and the resulting product is now in Phase III clinical studies via our licensee Nuron Biotech. The presentation will review the effectiveness of high pressure treatment for the reduction of aggregates and subvisible particulates in final formulations, examine the correlations between reduced aggregate levels and immunogenicity, and discuss the applications of high pressure treatment for other biosimilar candidates.
high pressure treatment for the reduction of aggregates and subvisible particulates in final formulations,